TPO and autoimmune thrombocytopenic purpura: These results were corroborated in an independent study that included 18 patients with refractory primary ITP in which the combination of an immunosuppressant (CsA or MMF) and a TPO-RA (eltrombopag/romiplostim) showed an efficacy of 72% (13 of 18 patients) [119].